217 related articles for article (PubMed ID: 29157828)
21. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series.
Gardin NE
Phytother Res; 2009 Mar; 23(3):407-11. PubMed ID: 19003944
[TBL] [Abstract][Full Text] [Related]
22. Proteomic fingerprinting of mistletoe (Viscum album L.) via combinatorial peptide ligand libraries and mass spectrometry analysis.
Vergara-Barberán M; Lerma-García MJ; Nicoletti M; Simó-Alfonso EF; Herrero-Martínez JM; Fasoli E; Righetti PG
J Proteomics; 2017 Jul; 164():52-58. PubMed ID: 28571969
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
Melzer J; Iten F; Hostanska K; Saller R
Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
[TBL] [Abstract][Full Text] [Related]
24. Safety of Combined Targeted and Helixor
Schad F; Thronicke A
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767928
[TBL] [Abstract][Full Text] [Related]
25. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy.
Kirsch A; Hajto T
J Altern Complement Med; 2011 Oct; 17(10):973-9. PubMed ID: 22010781
[TBL] [Abstract][Full Text] [Related]
26. Disappearance of an advanced adenomatous colon polyp after intratumoural injection with Viscum album (European mistletoe) extract: a case report.
von Schoen-Angerer T; Goyert A; Vagedes J; Kiene H; Merckens H; Kienle GS
J Gastrointestin Liver Dis; 2014 Dec; 23(4):449-52. PubMed ID: 25532007
[TBL] [Abstract][Full Text] [Related]
27. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival.
Tröger W; Galun D; Reif M; Schumann A; Stanković N; Milićević M
Eur J Cancer; 2013 Dec; 49(18):3788-97. PubMed ID: 23890767
[TBL] [Abstract][Full Text] [Related]
28. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro.
Weissenstein U; Kunz M; Urech K; Regueiro U; Baumgartner S
BMC Complement Altern Med; 2016 Aug; 16():271. PubMed ID: 27491866
[TBL] [Abstract][Full Text] [Related]
29. [Immunostimulatory properties of mistletoe extracts and their application in oncology].
Wrotek S; Skawiński R; Kozak W
Postepy Hig Med Dosw (Online); 2014 Oct; 68():1216-24. PubMed ID: 25380204
[TBL] [Abstract][Full Text] [Related]
30. Comparative study of the sensitivity of lymphoblastoid and transformed monocytic cell lines to the cytotoxic effects of Viscum album extracts of different origin.
Duong Van Huyen JP; Delignat S; Kazatchkine MD; Kaveri SV
Chemotherapy; 2003 Dec; 49(6):298-302. PubMed ID: 14671430
[TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins.
Duong Van Huyen JP; Bayry J; Delignat S; Gaston AT; Michel O; Bruneval P; Kazatchkine MD; Nicoletti A; Kaveri SV
Mol Med; 2002 Oct; 8(10):600-6. PubMed ID: 12477970
[TBL] [Abstract][Full Text] [Related]
32. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
Büssing A
Arzneimittelforschung; 2006 Jun; 56(6A):508-15. PubMed ID: 16927532
[TBL] [Abstract][Full Text] [Related]
33. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts.
Büssing A; Stumpf C; Tröger W; Schietzel M
Anticancer Res; 2007; 27(4C):2903-10. PubMed ID: 17695469
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines.
Urech K; Buessing A; Thalmann G; Schaefermeyer H; Heusser P
Anticancer Res; 2006; 26(4B):3049-55. PubMed ID: 16886633
[TBL] [Abstract][Full Text] [Related]
35. Phytochemical profile and therapeutic potential of Viscum album L.
Nazaruk J; Orlikowski P
Nat Prod Res; 2016; 30(4):373-85. PubMed ID: 25813519
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.
Thronicke A; Reinhold T; von Trott P; Grah C; Matthes B; Matthes H; Schad F
PLoS One; 2020; 15(7):e0236426. PubMed ID: 32716969
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.
Mabed M; El-Helw L; Shamaa S
Br J Cancer; 2004 Jan; 90(1):65-9. PubMed ID: 14710208
[TBL] [Abstract][Full Text] [Related]
38. [Mistletoe in the treatment of cancer patients].
Rostock M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo.
Cebović T; Spasić S; Popović M
Phytother Res; 2008 Aug; 22(8):1097-103. PubMed ID: 18570233
[TBL] [Abstract][Full Text] [Related]
40. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.).
Hutt N; Kopferschmitt-Kubler M; Cabalion J; Purohit A; Alt M; Pauli G
Allergol Immunopathol (Madr); 2001; 29(5):201-3. PubMed ID: 11720654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
